New results from the PROTECTED TAVR trial raised doubts about the future application of cerebral embolic protection (CEP) during transcatheter aortic valve replacement (TAVR).
TCT 2022: Trial Of Boston Scientific’s TAVR Embolic Protector Misses Endpoint, But May Offer 'Hope'
New trial data shows Boston Scientific’s Sentinel cerebral embolic protection device may reduce the risk of disabling stroke, but it does not appear to reduce the overall risk of stroke.
